Q-omics provides the consensus-scored C9orf57 profile across patient tissues and cancer cell-line models. C9orf57 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, C9orf57 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, C9orf57 RNA expression shows 6,094 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, KIRC, and STAD as cancer lineages where C9orf57 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C9orf57 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C9orf57 survival associations across molecular data types. C9orf57 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C9orf57 RNA expression–survival associations across cancer types. High C9orf57 expression shows unfavorable associations in THCA, ACC, UVM, KIRP and CESC, but favorable associations in LAML. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for C9orf57 RNA expression.
This table summarizes C9orf57 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for C9orf57. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C9orf57 shows lower tumor expression in LUSC and higher tumor expression in KIRC, COAD, LIHC, ESCA and HNSC. The KIRC box plot shows higher C9orf57 RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p = .001).
This table shows molecular features associated with C9orf57 in patient tissues and cancer cell lines. In patient samples, C9orf57 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C9orf57 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
